Related Experiment Videos
IgD kappa myeloma: a new case.
Bouchra Amine1, Karima Benbouazza, Taoufik Harzy
1Rheumatology department B, El Ayachi Hospital, Ibn Sina Teaching Hospital Center, Rabat-Salé, Morocco. amine_bouchra@yahoo.fr
Joint Bone Spine
|August 4, 2004
Summary
This case report details a rare IgD kappa myeloma, a severe form of multiple myeloma. Diagnosis can be challenging due to faint monoclonal proteins, highlighting the need for advanced testing.
Area of Science:
- Hematology
- Oncology
Background:
- IgD myeloma is a rare and aggressive subtype of multiple myeloma, accounting for 1-3% of all cases.
- The kappa subtype of IgD myeloma is even rarer, representing only 10-30% of IgD myeloma cases.
Observation:
- A 59-year-old male presented with severe low back pain, sciatica, diffuse bone pain, and a significant decline in general health.
- Laboratory findings included elevated ESR, aplastic anemia, hypercalcemia, and acute kidney injury.
- Serum protein electrophoresis was inconclusive, but immunoelectrophoresis revealed a faint IgD kappa band in serum and kappa light chains in urine.
Findings:
- Bone marrow examination showed 30% malignant plasma cells, confirming multiple myeloma.
- Radiographs revealed multiple punched-out bone lesions.
- The patient received symptomatic treatment for hypercalcemia and initiated combination chemotherapy.
Implications:
- IgD kappa myeloma is associated with severe outcomes, including extraosseous lesions, renal failure, and amyloidosis.
- The diagnosis of IgD myeloma can be difficult due to absent or faint monoclonal components on standard electrophoresis.
- Further research into the pathogenesis and improved treatment strategies for this aggressive myeloma variant is warranted.